The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we present the top 10 priorities for our field that were discussed at the meeting, and also detail a potential path forward to address these challenges. Defining robust predictors of cardiotoxicity, clarifying the role of cardioprotection, managing and preventing thromboembolism, improving hematopoietic stem cell transplant outcomes, personalizing cardiac interventions, building the cardio-oncology community, detecting and treating cardiovascular events associated with immunotherapy, understanding tyrosine kinase inhibitor cardiotoxicity, and enhancing survivorship care are all priorities for the field. The path forward requires a commitment to research, education, and excellence in clinical care to improve our patients' lives.
Keywords: CV, cardiovascular; CVD, cardiovascular disease; DOAC, direct oral anticoagulant; GCOS, Global Cardio-Oncology Summit; GLS, global longitudinal strain; HCT, hematopoietic cell transplantation; ICI, immune checkpoint inhibitor; LVEF, left ventricular ejection fraction; PD-1, programmed cell death 1 or its ligand; PD-L1, programmed cell death ligand 1; TKI, tyrosine kinase inhibitor; VTE, venous thromboembolism; anthracycline; antiangiogenic therapy; bone marrow transplantation; breast cancer; cancer survivorship; immunotherapy; thrombosis; tyrosine kinase inhibitor.
© 2019 The Authors.